G6PD and Parkinson disease: Hence, expression and activity of G6PD were elevated in an in vitro model of PD (e.g., LPS‐treated midbrain neuron–glial cultures) and the SN of vivo PD models, associating with microglial activation and mDAn neurodegeneration, whereas inhibition of G6PD elevation or knockdown of microglial G6PD attenuated LPS‐elicited chronic mDAn neurodegeneration (Tu et al., 2019).